Oxcarbazepine: Difference between revisions
(contraindications) |
(serious adverse effects) |
||
| Line 76: | Line 76: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*hyponatremia | |||
*anaphylaxis | |||
*angioedema | |||
*drug rxn w/ eosinophilia and systemic sx | |||
*Stevens-Johnson syndrome | |||
*toxic epidermal necrolysis | |||
*erythema multiforme | |||
*acute generalized exanthematous pustulosis | |||
*suicidality | |||
*leukopenia | |||
*thrombocytopenia | |||
*pancytopenia | |||
*agranulocytosis | |||
*aplastic anemia | |||
*pancreatitis | |||
*withdrawal seizures if abrupt D/C | |||
*withdrawal sx if abrupt D/C | |||
===Common=== | ===Common=== | ||
Revision as of 01:36, 11 February 2016
Administration
- Type: anti epileptic
- Dosage Forms: 150,300,600; 300/5 mL
- Routes of Administration: PO
- Common Trade Names: Trileptal
Adult Dosing
Partial seizures
- adjunct tx: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day;
- conversion to monotherapy: Dose: 1200 mg PO bid; Start: 300 mg PO bid, incr. by up to 600 mg/day qwk; Max: 2400 mg/day; D/C concomitant anticonvulsants over 3-6wk; taper dose gradually to D/C
- initial monotherapy: Dose: 600 mg PO bid; Start: 300 mg PO bid, incr. by 300 mg/day q3 days; Max: 2400 mg/day
Trigeminal neuralgia
- 450-1200 mg PO bid
- Start: 300 mg PO bid, may incr. by 600 mg/day qwk
Bipolar disorder
- 600-1200 mg PO bid
- Start: 300 mg PO bid, incr. by 300 mg/day q3 days or by 600 mg/day qwk
Pediatric Dosing
Partial seizures
adjunct therapy
- 2-3 yo
- Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. dose over 2-4wk; Max: 60 mg/kg/day
- may start 16-20 mg/kg/day PO divided bid in pts <20 kg
- 4-16 yo, 20-29 kg
- Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk
- 4-16 yo, >39 kg
- Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, incr. to target dose over 2wk
monotherapy
- 4-16 yo, 20-24 kg
- Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 25-34 kg
- Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 35-44 kg
- Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 45-49 kg
- Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 50-59 kg
- Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, 60-69 kg
- Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
- 4-16 yo, >70 kg
- Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, incr. by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
- D/C concomitant anticonvulsants over 3-6wk
Special Populations
- Pregnancy Rating: C
- Lactation risk: safety unknown
Renal Dosing
- Adult: CrCl <30: start 150 mg bid; HD/PD: no supplement; Info: titrate dose slowly until response
- Pediatric: CrCl <30: decr. start dose 50%, max start dose 300 mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response
Hepatic Dosing
- Adult: mild-mod impairment: no adjustment; severe impairment: not defined
- Pediatric: mild-mod impairment: no adjustment; severe impairment: not defined
Contraindications
- Allergy to class/drug
- HLA-B*1502 allele (tx-naive pts)
- avoid abrupt withdrawal
- caution if hypersens. to carbamazepine
- caution in elderly pts
- caution in pregnancy
- caution if hyponatremia
- caution if renal impairment
- caution if depression or hx
Adverse Reactions
Serious
- hyponatremia
- anaphylaxis
- angioedema
- drug rxn w/ eosinophilia and systemic sx
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- erythema multiforme
- acute generalized exanthematous pustulosis
- suicidality
- leukopenia
- thrombocytopenia
- pancytopenia
- agranulocytosis
- aplastic anemia
- pancreatitis
- withdrawal seizures if abrupt D/C
- withdrawal sx if abrupt D/C
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
